The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1.
 
Kun Wang
No Relationships to Disclose
 
XiWen Bi
No Relationships to Disclose
 
Guangyu Liu
No Relationships to Disclose
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Pfizer
Research Funding - Eisai
 
Shintaro Takao
No Relationships to Disclose
 
Sung Hoon Sim
No Relationships to Disclose
 
Young-Hyuck Im
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Sung Gwe Ahn
No Relationships to Disclose
 
Jeong Eon Lee
Research Funding - PROTEINA
 
Yeon Hee Park
No Relationships to Disclose
 
Manabu Futamura
No Relationships to Disclose
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Devicor Medical Products; Eisai; Exact Sciences; Konica Minolta; Kyowa Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Shimadzu; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Athenex; Bertis; BMS; Daiichi Sankyo; Kansai Medical; Kyowa Kirin; Lilly; Lux Biosciences; Lux Biosciences; Terumo
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Shimadzu; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Travel, Accommodations, Expenses - Eisai; Takeda
Other Relationship - Japan Breast Cancer Research Group; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research
 
Yasuhiro Fujiwara
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Santen; SRL Diagnostics
 
Mari Saito-Oba
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Astellas Pharma; Chugai Pharma; DAINIPPON SUMITOMO PHARMA Co., Ltd.; EA Pharma; Eisai; Kaken Pharmaceutical; Nihon Pharma; Ono Pharmaceutical; Otsuka; Otsuka; Sanofi; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; Yakult Honsha
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); DAINIPPON SUMITOMO PHARMA Co., Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)
 
Masahiko Nishiyama
No Relationships to Disclose
 
Shigeru Imoto
No Relationships to Disclose